Consolidated Financial Data (10 Years)

(¥ billion)

(Fiscal years)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
For the year:										
Net sales	252.6	249.8	281.9	293.5	301.9	305.0	363.7	410.5	461.5	**508.6**
Operating profit	60.7	51.7	59.0	61.2	55.2	50.0[5]	67.4	73.6	78.3	**87.5**
Profit attributable to owners of the parent	39.2	40.6	39.2	41.2	34.8	31.9[5]	44.0	45.7	49.6	**53.6**
Capital expenditure[1]	21.4	19.3	24.9	30.2	27.1	25.7	33.2	42.0	50.8	**48.6**
Depreciation and amortization	12.1	12.3	14.6	15.8	23.9	25.5	27.4	31.8	35.8	**39.0**
R&D expenses	15.4	15.5	16.7	19.5	21.7	22.5	26.7	31.0	31.4	**31.4**
Net cash provided by (used in) operating activities	41.7	32.8	52.2	44.7	53.1[4]	56.8[5]	58.7	68.8	63.9	**88.2**
Net cash provided by (used in) investing activities	(23.8)	(19.4)	(37.8)	(40.1)	(25.9)	(29.1)[5]	(35.0)	(51.7)	(54.9)	**(52.4)**
Net cash provided by (used in) financing activities	(8.7)	(10.8)	(11.5)	(14.0)	(20.5)[4]	(20.2)	(20.5)	(24.2)	(9.0)	**(24.3)**
At year-end:										
Total assets	263.9	279.8	321.9	346.7	389.2[4]	424.8[5]	483.7	531.0	618.9	**665.2**
Cash and cash equivalents, end of year	56.4	57.9	61.4	51.0	56.5	66.4	73.7	69.4	75.5	**89.5**
Total equity	182.8	210.2	241.4	265.1	278.3	306.0[5]	349.0	388.3	432.8	**464.5**
Interest-bearing liabilities	1.3	1.1	0.9	0.8	23.1[4]	22.5	22.8	23.5	56.3	**66.0**
Per share data:										
Equity attributable to owners of the parent[2] (yen)	293.11	335.29	384.86	422.36	443.26	486.96[5]	554.95	617.56	692.94	**743.71**
Profit attributable to owners of the parent (basic)[2] (yen)	63.03	65.10	62.76	65.87	55.70	50.91[5]	70.29	72.94	79.27	**86.07**
Profit attributable to owners of the parent (diluted)[2] (yen)	62.77	64.91	62.61	65.76	55.64	50.82[5]	70.16	72.91	79.24	**86.05**
Cash dividends applicable to the year[2] (yen)	17.33	19.33	22.00	23.33	24.00	24.00	25.33	27.33	28.00	**32.00**
Dividend payout ratio (%)	27.5	29.7	35.1	35.4	43.1	47.1[5]	36.0	37.5	35.4	**37.4**
Other data:										
Operating margin (%)	24.0	20.7	21.0	20.9	18.3	16.4[5]	18.5	17.9	17.0	**17.2**
Overseas sales ratio (%)	84.2	82.6	84.0	85.0	84.5	84.0	84.7	85.4	86.5	**86.7**
Equity ratio (%)	69.3	74.8	74.8	76.3	71.3	71.9[5]	72.0	73.0	69.8	**69.7**
Return on equity (ROE) (%)	23.1	20.7	17.4	16.3	12.9	10.9[5]	13.5	12.4	12.1	**12.0**
Return on assets (ROA)[3] (%)	15.7	14.9	13.0	12.3	9.5	7.8[5]	9.7	9.0	8.6	**8.4**
Number of employees (Including part-time and other employees)	7,446	7,930	8,445	8,715	9,231	9,510	9,812	10,522	11,012	**11,457**
Exchange rates:										
US dollars (yen)	120.1	108.4	110.9	110.9	108.7	106.1	112.4	135.5	144.6	**152.6**
Euros (yen)	132.6	118.8	129.7	128.4	120.8	123.7	130.6	141.0	156.8	**163.8**
Chinese Yuan (yen)	18.9	16.1	16.8	16.5	15.6	15.7	17.5	19.8	20.1	**21.1**

1 Including tangible and intangible items
2 Dividend (actual) converted to post-split basis. As of April 1, 2024 (Three-for-one stock split).
3 ROA = Profit attributable to owners of the parent/total assets (yearly average)×100
4 Adopted IFRS 16 (from fiscal 2019)
5 In fiscal 2021, Sysmex changed its accounting policy for configuration or customization costs in cloud computing contracts to recognize costs as expenses when services are received. Accordingly, we have by retroactively adjusted the figures for the fiscal 2020.

Consolidated Statement of Financial Position

Sysmex Corporation and Its Subsidiaries
As of March 31, 2025

	Millions of Yen		Thousands of U.S. Dollars
	2025	2024	2025
Assets			
Current assets			
Cash and cash equivalents	**¥ 89,570**	¥ 75,507	**$ 597,133**
Trade and other receivables	**163,007**	157,067	**1,086,713**
Inventories	**81,811**	79,123	**545,407**
Other short-term financial assets	**654**	1,310	**4,360**
Income taxes receivable	**1,246**	934	**8,307**
Other current assets	**28,531**	29,515	**190,207**
Total current assets	**364,821**	343,459	**2,432,140**
Non-current assets			
Property, plant and equipment	**130,211**	116,693	**868,073**
Goodwill	**14,205**	17,221	**94,700**
Intangible assets	**92,146**	86,786	**614,307**
Investments accounted for using the equity method	**339**	472	**2,260**
Trade and other receivables	**26,978**	21,435	**179,853**
Other long-term financial assets	**12,034**	14,034	**80,227**
Asset for retirement benefits	**0**	458	**0**
Other non-current assets	**6,880**	4,339	**45,867**
Deferred tax assets	**17,651**	14,018	**117,673**
Total non-current assets	**300,447**	275,461	**2,002,980**
Total assets	**¥665,268**	¥618,920	**$4,435,120**
Liabilities and equity			
Liabilities			
Current liabilities			
Trade and other payables	**¥ 31,865**	¥ 33,602	**$ 212,433**
Lease liabilities	**9,250**	8,659	**61,667**
Other short-term financial liabilities	**1,403**	1,028	**9,353**
Income taxes payable	**12,784**	12,476	**85,227**
Provisions	**1,164**	1,159	**7,760**
Contract liabilities	**18,098**	16,591	**120,653**
Accrued expenses	**22,355**	21,643	**149,033**
Accrued bonuses	**14,709**	12,611	**98,060**
Other current liabilities	**11,194**	10,311	**74,627**
Total current liabilities	**122,826**	118,084	**818,840**
Non-current liabilities			
Long-term loans payable	**32,359**	28,600	**215,727**
Lease liabilities	**23,126**	18,080	**154,173**
Other long-term financial liabilities	**56**	76	**373**
Liability for retirement benefits	**2,127**	2,239	**14,180**
Provisions	**1,054**	674	**7,027**
Other non-current liabilities	**11,608**	10,350	**77,387**
Deferred tax liabilities	**7,575**	7,917	**50,500**
Total non-current liabilities	**77,908**	67,938	**519,387**
Total liabilities	**200,734**	186,023	**1,338,227**
Equity			
Equity attributable to owners of the parent			
Capital stock	**14,887**	14,729	**99,247**
Capital surplus	**20,960**	20,830	**139,733**
Retained earnings	**402,820**	365,985	**2,685,467**
Treasury stock	**(12,318)**	(12,315)	**(82,120)**
Other components of equity	**37,425**	42,814	**249,500**
Total equity attributable to owners of the parent	**463,776**	432,045	**3,091,840**
Non-controlling interests	**758**	851	**5,053**
Total equity	**464,534**	432,897	**3,096,893**
Total liabilities and equity	**¥665,268**	¥618,920	**$4,435,120**

Note: The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥150 to $1, the approximate rate of exchange at March 31, 2025.

Consolidated Statement of Income

Sysmex Corporation and Its Subsidiaries
For the Year Ended March 31, 2025

	Millions of Yen		Thousands of U.S. Dollars
	2025	2024	2025
Net sales	**¥508,643**	¥461,510	**$3,390,953**
Cost of sales	**236,665**	219,013	**1,577,767**
Gross profit	**271,977**	242,497	**1,813,180**
Selling, general and administrative expenses	**150,848**	133,798	**1,005,653**
Research and development expenses	**31,455**	31,402	**209,700**
Impairment losses	**3,211**	2,210	**21,407**
Other operating income	**2,070**	4,203	**13,800**
Other operating expenses	**948**	905	**6,320**
Operating profit	**87,583**	78,382	**583,887**
Financial income	**1,078**	937	**7,187**
Financial expenses	**3,518**	2,386	**23,453**
Share of loss on equity method	**(2,071)**	(2,849)	**(13,807)**
Foreign exchange gain (loss)	**(3,850)**	516	**(25,667)**
Profit before tax	**79,221**	74,600	**528,140**
Income tax expenses	**25,645**	24,826	**170,967**
Profit	**¥ 53,576**	¥ 49,774	**$ 357,173**
Profit attributable to			
Owners of the parent	**¥ 53,669**	¥ 49,639	**$ 357,793**
Non-controlling interests	**(93)**	135	**(620)**
Profit	**¥ 53,576**	¥ 49,774	**$ 357,173**

	Yen		U.S. Dollars
	2025	2024	2025
Earnings per share			
Basic	**¥ 86.07**	¥ 79.27	**$ 0.57**
Diluted	**86.05**	79.24	**0.57**

Note: The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥150 to $1, the approximate rate of exchange at March 31, 2025.

Consolidated Statement of Comprehensive Income

Sysmex Corporation and Its Subsidiaries
For the Year Ended March 31, 2025

	Millions of Yen		Thousands of U.S. Dollars
	2025	2024	2025
Profit	**¥53,576**	¥49,774	**$357,173**
Other comprehensive income (loss)			
Items that will not be reclassified subsequently to profit or loss			
Net gain (loss) on financial assets measured at fair value through other comprehensive income	**(2,194)**	250	**(14,627)**
Remeasurements of defined benefit plans	**(114)**	(181)	**(760)**
Total	**(2,308)**	69	**(15,387)**
Items that may be reclassified subsequently to profit or loss			
Exchange differences on translation of foreign operations	**(1,830)**	23,526	**(12,200)**
Share of other comprehensive income of investments accounted for using the equity method	**(3)**	27	**(20)**
Total	**(1,833)**	23,553	**(12,220)**
Total other comprehensive income	**(4,141)**	23,623	**(27,607)**
Comprehensive income	**¥49,434**	¥73,397	**$329,560**
Comprehensive income attributable to			
Owners of the parent	**¥49,527**	¥73,262	**$330,180**
Non-controlling interests	**(93)**	135	**(620)**
Comprehensive income	**¥49,434**	¥73,397	**$329,560**

Note: The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥150 to $1, the approximate rate of exchange at March 31, 2025.

Consolidated Statement of Changes in Equity

Sysmex Corporation and Its Subsidiaries
For the Year Ended March 31, 2025

	Millions of Yen							
	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of March 31, 2023	¥14,282	¥20,580	¥334,192	¥ (314)	¥18,925	¥387,665	¥690	¥388,356
Profit	—	—	49,639	—	—	49,639	135	49,774
Other comprehensive income (loss)	—	—	—	—	23,623	23,623	0	23,623
Comprehensive income (loss)	—	—	49,639	—	23,623	73,262	135	73,397
Exercise of warrants	447	255	—	—	—	703	—	703
Cash dividends	—	—	(17,579)	—	—	(17,579)	—	(17,579)
Purchase of treasury stock	—	—	—	(12,001)	—	(12,001)	—	(12,001)
Transfer to retained earnings	—	—	(266)	—	266	—	—	—
Changes from business combination	—	—	—	—	—	—	87	87
Changes due to acquisition of control of a subsidiary	—	(5)	—	—	—	(5)	(62)	(67)
Changes due to loss of control of a subsidiary	—	—	—	—	—	—	(0)	(0)
Total transactions with the owners	447	250	(17,845)	(12,001)	266	(28,882)	25	(28,857)
As of March 31, 2024	**¥14,729**	**¥20,830**	**¥365,985**	**¥(12,315)**	**¥42,814**	**¥432,045**	**¥851**	**¥432,897**
Profit	**—**	**—**	**53,669**	**—**	**—**	**53,669**	**(93)**	**53,576**
Other comprehensive income (loss)	**—**	**—**	**—**	**—**	**(4,141)**	**(4,141)**	**—**	**(4,141)**
Comprehensive income (loss)	**—**	**—**	**53,669**	**—**	**(4,141)**	**49,527**	**(93)**	**49,434**
Exercise of warrants	**158**	**90**	**—**	**—**	**—**	**248**	**—**	**248**
Share-based payment transactions	**—**	**39**	**—**	**—**	**—**	**39**	**—**	**39**
Cash dividends	**—**	**—**	**(18,081)**	**—**	**—**	**(18,081)**	**—**	**(18,081)**
Purchase of treasury stock	**—**	**—**	**—**	**(2)**	**—**	**(2)**	**—**	**(2)**
Disposal of treasury stock	**—**	**0**	**—**	**0**	**—**	**0**	**—**	**0**
Transfer to retained earnings	**—**	**—**	**1,247**	**—**	**(1,247)**	**—**	**—**	**—**
Total transactions with the owners	**158**	**129**	**(16,834)**	**(2)**	**(1,247)**	**(17,796)**	**—**	**(17,796)**
As of March 31, 2025	**¥14,887**	**¥20,960**	**¥402,820**	**¥(12,318)**	**¥37,425**	**¥463,776**	**¥758**	**¥464,534**

	Thousands of U.S. Dollars							
	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of March 31, 2024	**$98,193**	**$138,867**	**$2,439,900**	**$(82,100)**	**$285,427**	**$2,880,300**	**$5,673**	**$2,885,980**
Profit	**—**	**—**	**357,793**	**—**	**—**	**357,793**	**(620)**	**357,173**
Other comprehensive income (loss)	**—**	**—**	**—**	**—**	**(27,607)**	**(27,607)**	**—**	**(27,607)**
Comprehensive income (loss)	**—**	**—**	**357,793**	**—**	**(27,607)**	**330,186**	**(620)**	**329,560**
Exercise of warrants	**1,053**	**600**	**—**	**—**	**—**	**1,653**	**—**	**1,653**
Share-based payment transactions	**—**	**260**	**—**	**—**	**—**	**260**	**—**	**260**
Cash dividends	**—**	**—**	**(120,540)**	**—**	**—**	**(120,540)**	**—**	**(120,540)**
Purchase of treasury stock	**—**	**—**	**—**	**(13)**	**—**	**(13)**	**—**	**(13)**
Disposal of treasury stock	**—**	**0**	**—**	**0**	**—**	**0**	**—**	**0**
Transfer to retained earnings	**—**	**—**	**8,313**	**—**	**(8,313)**	**—**	**—**	**—**
Total transactions with the owners	**1,053**	**860**	**(112,227)**	**(13)**	**(8,313)**	**(118,640)**	**—**	**(118,640)**
As of March 31, 2025	**$99,247**	**$139,733**	**$2,685,467**	**$(82,120)**	**$249,500**	**$3,091,840**	**$5,053**	**$3,096,893**

Note: The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥150 to $1, the approximate rate of exchange at March 31, 2025.

Consolidated Statement of Cash Flows

Sysmex Corporation and Its Subsidiaries
For the Year Ended March 31, 2025

	Millions of Yen		Thousands of U.S. Dollars
	2025	2024	**2025**
Operating activities			
Profit before tax	**¥ 79,221**	¥ 74,600	**$ 528,140**
Depreciation and amortization	**39,033**	35,888	**260,220**
Impairment loss	**3,211**	2,210	**21,407**
Interest and dividend income	**(899)**	(863)	**(5,993)**
Interest expenses	**1,949**	1,571	**12,993**
Share of loss on equity method	**2,071**	2,849	**13,807**
Loss on disposal of property, plant and equipment	**383**	381	**2,553**
Increase in trade receivables	**(7,150)**	(21,987)	**(47,667)**
Decrease in advance payments	**706**	474	**4,707**
Increase in inventories	**(6,320)**	(1,676)	**(42,133)**
Increase in trade payables	**162**	1,274	**1,080**
Increase (decrease) in accounts payable – other	**(520)**	118	**(3,467)**
Increase in contract liabilities	**1,720**	201	**11,467**
Increase in accrued expenses	**1,113**	1,483	**7,420**
Decrease/increase in consumption taxes receivable/payable	**(1,374)**	1,157	**(9,160)**
Increase in accrued bonuses	**2,118**	749	**14,120**
Other – net	**1,743**	(4,769)	**11,620**
Subtotal	**117,168**	93,665	**781,120**
Interest and dividend received	**654**	598	**4,360**
Interest paid	**(1,853)**	(1,383)	**(12,353)**
Income taxes paid	**(27,723)**	(28,974)	**(184,820)**
Net cash provided by operating activities	**88,246**	63,905	**588,307**
Investing activities			
Purchase of property, plant and equipment	**(29,226)**	(25,610)	**(194,840)**
Proceeds from sales of property, plant and equipment	**702**	527	**4,680**
Purchase of intangible assets	**(20,733)**	(24,581)	**(138,220)**
Increase in long-term prepaid expenses	**(1,001)**	(841)	**(6,673)**
Purchase of investments in equity instruments	**(3,821)**	(4,026)	**(25,473)**
Proceeds from the sale of equity instruments	**1,853**		**12,353**
Acquisitions of subsidiaries or other businesses		(574)	
Payments into time deposits	**(1,544)**	(1,460)	**(10,293)**
Proceeds from withdrawal of time deposits	**1,777**	1,260	**11,847**
Other – net	**(495)**	337	**(3,300)**
Net cash used in investing activities	**(52,488)**	(54,970)	**(349,920)**
Financing activities			
Proceeds from long-term loans payable	**4,700**	29,000	**31,333**
Repayments of long-term loans payable	**(626)**		**(4,173)**
Exercise of warrants	**248**	703	**1,653**
Purchase of treasury shares	**(2)**	(12,001)	**(13)**
Dividends paid	**(18,081)**	(17,579)	**(120,540)**
Repayment of lease liabilities	**(10,561)**	(9,068)	**(70,407)**
Other – net	**2**	(67)	**13**
Net cash used in financing activities	**(24,322)**	(9,013)	**(162,147)**
Foreign currency translation adjustments on cash and cash equivalents	**2,627**	6,125	**17,513**
Net increase in cash and cash equivalents	**14,062**	6,047	**93,747**
Cash and cash equivalents, beginning of year	**75,507**	69,460	**503,380**
Cash and cash equivalents, end of year	**¥ 89,570**	¥ 75,507	**$ 597,133**

Note: The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥150 to $1, the approximate rate of exchange at March 31, 2025.

Status of Sustainability Targets (Excerpted)

Please see the *Sysmex Sustainability Data book* for details about all sustainability targets and future initiatives.
>>Website > Sysmex Sustainability Data Book 2025 > Status of Sustainability Targets

Materiality		KPI[1]		Target			Results					Key Progress
				Fiscal 2024	Fiscal 2025	Fiscal 2033 (Eco-Vision)	Fiscal 2020	Fiscal 2021	Fiscal 2022	Fiscal 2023	Fiscal 2024	
Creating new value for a healthy society	Resolution of medical issues through innovation	Number of hematology tests	Number of CBC tests (based on the number of reagents)	—	—	—	—	2,971 million	2,977 million	3,325 million	3,322 million	● The number of hematology tests declined due to a temporary impact from a change in aggregation methods; however, our business continues to progress favorably. ● Market share increased due to growth in reagent sales driven by a rise in instrument installations across all regions, expansion in emerging markets such as India and Saudi Arabia, and progress in direct sales regions. The successful introduction of flagship models in Japan and EMEA also contributed to this growth. ● Sales of surgical robot system began overseas in fiscal 2024, and the number of cases increased dramatically, primarily in Japan, due to an increase in the number of installations. ● The number of cancer genomes analyzed and the number of breast cancer testing using the OSNA method have been steadily progressing. ● Through the strengthening of our sales and service structure in emerging countries such as India, Brazil, the Middle East, Turkey, and Saudi Arabia, sales in emerging and developing countries increased.
		Hematology market share[2]	Percentage of consolidated sales to the market size of instruments, reagents, and services in a single year in the field of hematology	—	—		55.6%	54.6%	54.0%	53.0%	54.6%	
		Number of cases with surgical support robot	Number of cases with surgical robot system (manufactured by Medicaroid Corporation)	—	—		—	—	1,323	2,903	5,209	
		Number of cancer genomes Analyzed[3]	Number of cancer genomes analyzed by the NCC OncoPanel	—	—		1.6 thousand	1.6 thousand	1.7 thousand	1.6 thousand	1.8 thousand	
		Number of breast cancer tests using the OSNA method	Number of breast cancer tests using the OSNA method	—	—		46 thousand	54 thousand	52 thousand	52 thousand	53 thousand	
	Improvement in accessibility to healthcare	Sales in emerging and developing markets	Consolidated sales in emerging and developing markets	—	—		¥122.0 billion	¥143.0 billion	¥156.7 billion	¥164.6 billion	¥179.5 billion	
Providing responsible products, services, and solutions	Pursuit of quality and trust	Number of recalls[4]	Number of voluntary recalls/repairs for products sold (instruments and reagents)	—	—		8	3	7	4	6	● The number of recalls increased by two compared with the previous fiscal year; however, there were no health hazards. We successfully prevent defective products from entering the market by establishing a system that ensures compliance with the regulations of each country, timely collecting information, and thoroughly investigating the causes of defective products. ● The CSR survey response rate achieved target. In addition to working toward the improvement of initiatives based on the results of the CSR survey, we conducted training sessions on the CSR survey and BCP response items. We also held an SBT briefing session.
	Strengthening supply chain management	CSR survey response rate (primary suppliers in Japan and overseas)	Percentage of raw material suppliers that responded to CSR surveys (primary suppliers in Japan and overseas)	90%	90%		89%	90%	94%	95%	95%	
Reducing environmental impacts	Resource circulation in product life cycle	Zero product loss	Unused disposal rate of in-house manufactured goods, raw materials and spare parts (cost/sales percentage)	0.20%	0.18%	Less than 0.1%	—	—	—	0.40%	0.40%	● As part of our efforts to achieve zero product loss, we established recycling systems in multiple regions for unused instruments that would otherwise be discarded. However, due to an increase in the disposal of COVID-19-related reagents and other items, the overall unused disposal rate remained at the same level as in the previous fiscal year. ● By fully switching to recycled and environmentally friendly materials, such as changing product packaging to recycled paper and FSC-certified paper, and replacing wooden pallets for instruments with cardboard, we exceeded our target. ● Scope 3 >>P76 ● With regard to the supplier engagement rate, a newly established target, we are working to achieve a rate of 60% within the next five years. ● Scope 1 and Scope 2 >>P76 In fiscal 2024, electricity usage increased due to the parallel operation of new and existing plants in India. As a result, the reduction rates did not meet our targets. ● Regarding the reduction of water consumption in reagent factories, we implemented measures such as improving tank and filter cleaning methods and enhancing pure water purification efficiency. As a result, we achieved a reduction that surpassed our target. ● With respect to the reduction of total waste, in addition to continuing existing initiatives, we exceeded our target through measures such as converting of waste items into valuable materials for recycling transactions in Japan.
		Recycling of containers and packing and utilization of environment compliance materials	Rate of recycled or environmentally conscious materials used in containers and packaging/labeling materials	50%	60.0%	100%	—	—	—	43%	62%	
		Reduction of greenhouse gas emissions (Scope 3)	Percentage of reduction of greenhouse gas emissions (Scope 3) with FY2022 as the base year	Cut 5%	Cut 10%	Cut 35%	—	—	—	Cut 4%	Cut 1%	
		Supplier engagement ratio[5]	The percentage of suppliers in Categories 1, 2, 4, and 9 that have obtained SBT certification or are committed to GHG emissions reductions equivalent to SBT	—	—	—	—	—	—	—	40%	
	Reduction in environmental burden through business activities	Reduction of greenhouse gas emissions (Scopes 1, 2)	Reduction rate of GHG emissions (Scope 1, 2) with FY2022 as the base year	Cut 35%	Cut 40%	Cut 55%	—	—	—	Cut 29%	Cut 33%	
		Reduction of water consumption (main reagent factories)	Percentage of reduction of water consumption per production of reagents with FY2022 as the base year	Cut 14pt	Cut 23pt	Cut 90pt	—	—	—	Up 2pt[4]	Cut 31pt	
		Reduction of total waste	Percentage of reduction waste generated by business activities per consolidated sales with FY2022 as the base year	Cut 3%	Cut 5%	Cut 15%	Cut 8%	Cut 15%	Cut 27%	Cut 32%	Cut 33%	
Creating an attractive workplace	Increased engagement	Engagement score	Percentage of positive responses to engagement in the corporate culture survey	75%	75%	—	66% (except EMEA)	65% (except EMEA)	71%	75%	76%	● Engagement score >>P67 ● While regions such as Japan saw improvements in the turnover ratio thanks to strengthened human resource development and a review of compensation structures, turnover increased in the United States, where business restructuring was undertaken. ● The female managers ratio exceeds 30% in overseas regions, notably in the Americas, due to the early appointment of women to managerial positions. On the other hand, the figure in Japan remains at 10%, showing differences in progress among regions. Going forward, to further accelerate the appointment of women to management positions, we will strengthen structural support measures such as the systematic development of management candidates and promotion to foster mindset change. ● In the whole Group's next-generation management positions remained at the same level as the previous fiscal year, reinforced by progress in overseas appointments. ● Value-added productivity >>P68
		Turnover ratio	Turnover rate of regular employees (Ratio for people who have left the organization for any reason, including layoffs, job cuts, job changes, retirement age, etc.)	10% or less	10% or less		7.5%	10.9%	8.4%	7.7%	8.0%	
	Promotion of diversity, equity & inclusion	Female managers ratio	Ratio of women at director level or above	19%or higher	20%or higher		16.2%	17.3%	19.5% (except Russia)	19.2%	18.7%	
		Female next generation managers ratio	Percentage of women in the manager position	—	—		—	—	32.1%	34.0%	34.0%	
		Female associates, employees ratio	Female associates, employees ratio	—	—		—	—	41.8%	41.5%	41.1%	
	Development of human resources	Value-added productivity (non-consolidated)[6]	Value added per time	—	—		—	—	¥13,230	¥14,760	¥15,042	
		Value-added productivity (Group)	Value added per capita	¥21.00 million	¥22.50 million		—	—	¥18.74 million	¥19.97 million	¥21.44 million	
Strengthening governance	Compliance	Number of internal reports	Number of internal reports of incidents received	—	—		12	28	21	26	17	● The number of internal reports totaled 17, including cases both in Japan and overseas. We investigated the facts of each case and took appropriate action. ● There were 19 unethical incidents, but no serious violations. Going forward, we will continue to position education and awareness-raising activities for employees as the foundation for promoting and ensuring compliance. We will also provide ongoing training and work to further instill conduct based on the Global Compliance Code.
		Number of unethical incidents	Total number of incidents in which the violations the law were found, and disciplinary actions were taken for the violation of the Global Compliance Code	—	—		5	14	9	15	19	

1 The shaded KPIs were added in April 2023. The items whose targets are displayed as "—" are monitoring items for which no targets are set.
2 Source: Clearstate and Sysmex estimates
3 Target: Sysmex Group in Japan
4 The figure disclosed in the previous fiscal year has been revised due to a change in the calculation method
5 Added KPIs from April 2024.
6 Target: Sysmex Corporation on a non-consolidated basis

Sysmex's Businesses

Diagnostics Business

Clinical testing, which is essential to healthcare, can be broadly divided into two categories: *in vitro* diagnostics (IVD) that involve the examination of blood, urine, and other samples taken from the body, and *in vivo* diagnostics, which involve direct examination using X-rays or electrocardiograms. Sysmex is developing its diagnostics business, centered on the IVD domain, where we provide medical institutions and other customers with instruments, reagents, and software on a global basis.

IVD is used in a variety of ways. It is used during medical checkups to help prevent disease. IVD is also used in diagnosing diseases, determining treatment methods, measuring the results of drug administration, predicting aggravation, and for post-treatment monitoring. Healthcare without accurate test results is like walking through fog; the path is uncertain. IVD is essential because it allows medical professionals to assess a patient's state of health accurately and swiftly, and to determine optimal treatment methods.

In IVD, within Sysmex's main business fields of hematology, urinalysis, and immunochemistry, testing is conducted to check a patient's physical condition. They are used for a wide range of other purposes, such as disease prevention and early-stage detection through medical checkups, and in treating diseases or managing their prognoses. In fields such as hemostasis and gene testing, tests are performed to measure a person's physical condition in greater detail and are mainly used in the process of diagnosing and treating diseases.

Medical Robotics Business

In recent years, it has become common to perform minimally invasive laparoscopic surgery to reduce the physical burden on patients. However, this surgery requires a high degree of technical skill, and surgical-support robots that complement these skills are attracting attention from medical workers. Currently, insurance coverage of surgical procedures using these robots has been extended to include urology, gastroenterology, gynecology, and respiratory surgery, and the number of surgeries performed using surgical support robots is gradually increasing. In addition, from the viewpoint of improving access to medical care, such robots are being considered for use with remote medicine. It may not be long before surgeries can be performed with doctors and patients in different locations.

Under these circumstances, Medicaroid Corporation, a joint venture between Sysmex and Kawasaki Heavy Industries, Ltd., developed the first made-in-Japan robotic-assisted surgery system. Sysmex began domestic sales of this system in 2020 as a global exclusive distributor and has since stepped up its market penetration. Internationally, the system obtained regulatory approval in Singapore in 2023 and in Malaysia in 2024. In the EMEA region, as well, Sysmex is pursuing regulatory approval and is actively promoting a global rollout.

■ Diagnostics Business Domain



1 Diagnostics used for medical checkups

What can be determined from samples (blood, urine, and cancer tissue)



Sysmex's Products in Use



1 Commercial Labs

Commercial labs conduct testing for small-scale medical institutions that do not have their own analyzers, as well as handling specialized tests. Large-scale labs, which handle tens of thousands of samples each day, use high-productivity transport systems.

2 Hospitals

In laboratories, our products for testing blood and urine are used for medical checkups and diagnosis of outpatients and inpatients. Operating rooms use our surgical robot systems and employ the OSNA method for cancer lymph node metastasis testing.

3 Clinics

Clinics typically use products that are compact and simple.

4 Universities and Research Institutions, etc. (Lab Assay Services)

We are developing a lab assay business, in which we receive samples from medical institutions, test them at our labs and our affiliated companies (such as Sysmex Inostics and RIKEN GENESIS), and send back the results of protein or gene analyses performed on those samples. In addition to medical institutions, we handle measurements on behalf of universities, research institutes, and pharmaceutical companies, providing information to assist their drug discovery and R&D efforts.

5 Veterinary hospitals

Our products are used in maintaining the health of dogs, cats, and other pets, as well as aquarium and zoo animals.

Primary Products and Services

Diagnostics Business

Hematology

For small- and medium-sized institutions, Sysmex offers three-part white blood cell differential models, used for determining basic parameters, as well as five-part white blood cell differential models, used to deliver a high degree of clinical significance and require numerous reagents. In addition, we offer a wide-ranging lineup, including transport systems that can be used for rapid, high-volume testing in large-scale labs. In Japan in 2021, we launched a new five-part white blood cell differential flagship model, as well as a compact model providing three-part white blood cell differentiation. In 2022, we launched sample transportation system modules equipped with the world's first automated measurement function for quality control materials. Sysmex has been moving forward with the global rollout of its flagship models since 2023. In June 2025, we obtained marketing approval for sales in the United States.

In 2018, we launched the first products to have received CLIA-waiver certification to clinics and other small-scale facilities in the United States. We are also rolling out products to help realize early-stage detection and treatment of malaria. In EMEA in 2019, and in Japan in 2020, we launched an analyzer that supports standardization and improved efficiency in malaria testing.

■ Product Lineup of Multiparameter Automated Hematology Analyzers



Flagship Model Boosts Efficiency in Laboratory Operations

In 1990, Sysmex developed the world's first fully automated hematology system, which automated everything from the counting of blood cells and the differentiation of white blood cells to smear preparation. This automation not only helped reduce labor costs but also helped reduce the risk of infection during sample handling and prevention of sample mix-ups. The flagship model we launched in 2021 improved processing capacity by 10% compared to the previous model, enhanced the ability to detect abnormal cells, and reduced power consumption by 40% (at maximum output of the transport system). Additionally, by combining peripheral devices based on the "touch-free concept," the system automates tasks such as device startup, quality control, and sample storage and retrieval, significantly minimizing manual work and further enhancing the efficiency of laboratory testing operations.

>>Three Growth Strategies, "Hematology" P51 >>R&D "Touch-Free Concept" P58

Analyzer and Sample Transportation System Product Lineup



Note: This is an example of equipment layout.

Flow Cytometry (FCM)

Flow cytometers using flow cytometry (FCM) technology are utilized not only in clinical fields for detailed analyses of leukemia, malignant lymphoma, HIV/AIDS, and similar conditions, but also in industrial applications such as food quality control, and in research fields such as cancer studies and regenerative medicine conducted by pharmaceutical companies and universities. In North America—the largest market for FCM testing—Sysmex launched a sample preparation system in 2019 and a flow cytometer for research use in 2020, achieving full automation of the FCM testing workflow from pretreatment to acquisition of measurement results. Going forward, Sysmex plans to further expand global deployment and maximize synergies between FCM and hematology testing, as the former is often performed as a follow-up to the latter.

Clinical flow cytometry system (flow cytometer, sample preparation system, etc.)

Antibody reagents (for research)

Urinalysis

We developed the world's first automated urine particle analyzer using the flow cytometry method. We are also adding to our portfolio of urine chemistry products by making use of alliances as we work to expand our lineup in response to diverse urinalysis needs. In 2020, we signed a distributorship agreement with Siemens Healthineers for the North American market. In 2022, we launched a new product in Japan for the mid/low-end market, which we have also rolled out in the EMEA region, and we plan to further expand our market scale.

Fully automated urine particle analyzer
Fully automated urine chemistry analyzer
Fully automated imaging unit for formed elements in urine

Reagents

Hemostasis

Sysmex handles products offering a wide range of processing capacities to meet the needs of various facilities. Demand for hemostasis testing has increased and grown more diverse due to a rise in thrombotic diseases stemming from lifestyle diseases, as well as to the development of new blood preparations.

Sysmex provides high-performance and user-friendly instruments, and is actively developing clinically valuable products in collaboration with Siemens Healthineers and Group company HYPHEN BioMed. In 2024, we commenced direct sales in this field in Europe and the United States.

Automated blood coagulation analyzer

Reagents

Immunochemistry

We are working to develop our business in Asia, including Japan and China, through sales of a fully automated immunoassay system, which performs highly sensitive, high-speed assays on minute sample quantities.

In addition to reagents to test for infectious disease and tumor markers, we are developing proprietary markers to test for measuring progression of hepatic fibrosis and atopic dermatitis. In 2022, we launched a reagent in Japan to test for Alzheimer's disease, which we are now rolling out in Europe and the United States. We are also working to develop new testing parameters.

In China we are working to differentiate ourselves by augmenting the number of parameters tailored to regional needs. To do so, we are pursuing development in local R&D bases and joint development with local companies.

Automated immunoassay system

Reagents

Cancer Gene Testing

Cancer Lymph Node Metastasis Testing System

Using our proprietary technology, the OSNA method, we provide a system that automatically and easily detect information to assist in diagnosing lymph node metastasis. We launched this system in China in 2020.

We developed a system for use in cancer gene profiling in collaboration with the National Cancer Center Japan. The system's targets for analysis are solid tumors. By obtaining a comprehensive cancer genomic profile of tumor tissue, the system analyzes abnormalities in cancer-specific genes in patients to provide information that is useful in determining treatment methods, including diagnoses and the selection of anti-cancer drugs. In 2019, this became the first such system to be covered under Japanese health insurance and be used in clinical settings.

Caresphere ICT Solution

Sysmex provides ICT solutions for healthcare professionals, including physicians and clinical laboratory technicians. We have built a platform that integrates and analyzes various types of data in real-time, from testing equipment and laboratory information systems to support laboratory operations. Our platform includes several applications, such as external quality control tools, services for visualizing equipment operation status and test volumes remotely, and educational tools. These tools support quality control and operational efficiency in laboratories, and also help reduce workloads at medical facilities and improve customer satisfaction through remote instrument maintenance and support.

Medical Robotics Business

Robotic-Assisted Surgery System

Compact enough to fit in standard Japanese operating rooms, this system is equipped with user-friendly robot arms and a high-definition 3D videoscope. Furthermore, the system has been designed to be network compatible, to support more accurate treatment by medical workers.

Robotic-assisted surgery system

Antimicrobial Susceptibility Testing

In June 2023, we launched in Europe a system to rapidly detect antimicrobial susceptibility. The system detects the presence or absence of bacteria and assesses the effectiveness of antimicrobials using urine samples from patients suspected of having urinary tract infections. This system delivers test results in as little as 30 minutes, compared with the several days that were previously required. This assists the appropriate use of antimicrobials during initial patient visits at clinics and other primary care settings.

Analyzer

Single use sample cartridge

Rapid antimicrobial susceptibility testing system

Rapid Antimicrobial Susceptibility Testing System Wins "Longitude Prize on AMR"

In June 2024, Sysmex Astrego AB was awarded the "Longitude Prize on AMR," the UK's largest science prize, for being the most innovative contributor to solving the global issue of antimicrobial resistance (AMR). This system challenges the conventional diagnostic flow for bacterial infections and was the sole winner selected from more than 250 applications submitted worldwide since the prize's inception in November 2014. Currently, Sysmex is working to prepare the system for clinical use by collecting data from healthcare institutions and building relationships with key opinion leaders. We will continue accelerating efforts to expand the system's global reach and its applications to additional disease areas.

From right: Mikael Olsson, CEO of Sysmex Astrego AB, and Mike Read, Deputy CEO

Stakeholder Engagement

Sysmex works alongside its business partners and employees to provide products and services to medical institutions and other customers in an effort to resolve medical and social issues. Going forward, through proactive dialogue with stakeholders, we strive to forge better relations. In addition, by incorporating their expectations and requirements into our business activities, we will enhance the effectiveness of our strategy and strive to realize a sustainable society.

Major Stakeholders

Stakeholders described outside the circle are categorized according to our Shared Values. >>P4



Main Dialogue with Stakeholders

>>Website >Sustainability >Sustainability Management >Stakeholder Engagement

Customers	We engage in ongoing communication through sales and service and support activities, with the aim of instilling confidence in our customers and providing added value that exceeds their expectations. As a result, we earn high marks in customer satisfaction surveys. >>Customer Assessment in the United States P62
Employees	To achieve sustainable growth, it is essential that we work on recruiting, developing, and deploying human resources, promoting diversity and inclusion, and creating a workplace that is comfortable, appealing and conducive to work, in line with our Long-Term Corporate Strategy 2033. We have set the engagement score on our corporate culture survey, as one of our sustainability targets, and we are undertaking initiatives to achieve this target. >>Human Capital Strategy P65
Business Partners	We maintain ongoing dialogues to foster an understanding among business partners of Sysmex's business direction and policies, as well as to build trust-based relationships. For suppliers, we are strengthening communication to realize a circular society, as well as establishing supply chain management in accordance with our procurement policy.
Shareholders	Sysmex recognizes that IR activities are important to achieving sustainable growth and medium- to long-term increases in corporate value. We strive to disclose information proactively and quickly share internally the evaluations and requests that we receive in the course of dialogues with shareholders and investors, and to reflect this information in our management and IR activities. In recent years, we have received valuable suggestions from our investors regarding improvements to capital efficiency and a revision to our rolling mid-term management plan, and we have incorporated this input into our initiatives.
Society	We liaise and engage in dialogue with government agencies and international organizations with a view to the development of healthcare and the realization of a sustainable society. In addition, we communicate with society at large through activities aimed at meeting the needs of communities around the world, based on our Policy on Corporate Citizenship Activities and Philanthropy.

Terminology

Antimicrobial resistance	This phenomenon occurs when living organisms develop a resistance to a drug, whose efficacy is decreased or neutralized as a result. Bacteria that have developed microbial resistance are known as antimicrobial-resistant bacteria.
Bio-reagents	These reagents are made from proteins and substances derived from living organisms. Bio-reagents are more difficult to produce than chemical reagents in terms of raw material variability and quality stability.
Commercial lab	A company that specializes in testing operations, performing IVD on behalf of medical institutions, research institutes, and other facilities.
Concentrated reagents	More concentrated than conventional reagents, these reagents are automatically diluted and adjusted by the testing system.
EMEA	Europe, the Middle East, and Africa
Flow Cytometry (FCM)	Method involving the flow dispersion of minute particles and the use of laser light to optically analyze minute flows.
Hematology	The field of *in vitro* diagnostics that determines whether precise testing is necessary, by analyzing the number, type, and size of red, white, and other blood cells.
in vitro diagnostics (IVD)	In general, IVD refers to the testing of blood, urine and other samples to determine physical condition. IVD may also refer to the domain of laboratory testing in which IVD is performed.
Laboratory developed test (LDT)	A test performed in the clinical laboratories of medical institutions, commercial labs, and other facilities based on their own quality control regulations.
Liquid biopsy	This is a general name for technology using blood or body fluid samples for diagnosis and the prediction of treatment impacts, rather than through the conventional practice of tissue biopsy, in which diagnosis is performed on diseased tissue that has been collected. Liquid biopsy is less invasive than tissue biopsy, but more highly sensitive detection technologies are required.
Panel testing	A test that allows multiple markers to be measured at once. Particularly in genomic medicine, cancer panels are used to analyze the mutation, proliferation, and fusion of multiple genes having diagnostic significance.
Precision management	A management method used to guarantee the values measured by customers' testing equipment and to confirm that a customer's equipment is functioning correctly. External quality control is a method under which the same specimens (such as artificially produced blood) are distributed to multiple clinical laboratories, and the measurement results obtained are analyzed using statistical methods, thereby allowing the precision of individual laboratories' measurement results to be evaluated. The results are provided as feedback to these laboratories, helping to increase the quality of testing.
Primary care	The initial care provided at clinics or other locations when a patient first falls ill.
Reagent	A pharmaceutical product for medical use in laboratory testing, also called an *in vitro* diagnostic product. It is not used directly on the human body, but on samples of blood or other bodily fluids.
Regulatory approval (manufacturing and marketing approval)	In Japan, the manufacturing and marketing of medical devices and reagents requires approval from the Ministry of Health, Labour and Welfare. Such approval necessitates confirmation of a product's function and safety. Other countries have their own regulatory procedures: approval from the Food and Drug Administration in the United States, obtaining the CE Mark in Europe (which indicates compliance with the *In Vitro* Diagnostic Medical Device Directive (IVDD) and the *In Vitro* Diagnostic Medical Device Regulation (IVDR)), and in China, approval from the National Medical Products Administration (NMPA).
Specimen	Material necessary for testing. May include blood, cerebrospinal fluid, pus, punctured fluid, urine and feces.
Transport system	A system that links multiple analyzers, allowing testing to be automated. In addition to making testing operations more efficient, automation helps reduce the risk of infection when samples are handled manually, and prevents mishandling.
Urine sediment testing	Testing performed to analyze formed elements in the urine, including blood and other cells. Urine chemistry testing, on the other hand, is conducted by using a test paper to analyze for the presence of sugar, protein, or blood cells in urine.

Stock Information (As of the End of Fiscal 2024)

■ Stock Price Range



■ Stock Price Movements

Fiscal years	High (Yen)	Low (Yen)	Closing price (Yen)	Volatility (%)
2014	6,880	3,070	6,670	27.6
2015	8,640	5,430	7,040	39.2
2016	8,170	6,010	6,750	29.9
2017	9,730	6,080	9,640	24.7
2018	11,110	4,810	6,690	38.7
2019	8,420	5,814	7,846	38.3
2020	13,310	7,024	11,925	27.7
2021	15,725	7,970	8,923	41.6
2022	9,815	7,380	8,643	41.0
2023[1]	10,440	2,637	2,662	29.8
2024	3,236	2,138	2,837	29.0

Note: Volatility refers to the annualized standard deviation based on daily closing prices.
1 Stock splits conducted on April 1, 2024 (1:3). (actually, the end of March)

■ Total Shareholder Return (TSR[1]) (Annualized Rate)

(%)

Investment period	Past 1 Year	Past 3 years		Past 5 years		Past 10 years	
	Cumulative/ Annual rate	Cumulative	Annual rate	Cumulative	Annual rate	Cumulative	Annual rate
Sysmex	7.7	(1.6)	(0.5)	13.4	2.6	39.1	3.4
TOPIX	(1.5)	47.2	13.8	113.4	16.4	117.4	8.1
TOPIX (Electrical equipment)	(3.4)	34.4	10.4	135.0	18.6	155.9	9.9

1 TSR: Total shareholder return, including capital gains and dividends
- Prepared by Sysmex based on data from Nikkei NEEDSFinancial QUEST
- Base date of March 31, 2025
- TSR calculated on the assumption that dividends are reinvested in shares

■ Principal Shareholders (Top 10)

Shareholders	Number of shares held (Thousands)	Percentage of shareholding (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	77,809	12.39
Nakatani Foundation	38,692	6.16
Custody Bank of Japan, Ltd. (Trust Account)	37,606	5.99
The Kobe Yamabuki Foundation	36,000	5.73
Nakatani Kosan, Ltd.	34,341	5.47
Taeko Wada	21,709	3.46
Kazuko Ietsugu	20,909	3.33
Rusoru, Ltd.	14,250	2.27
STATE STREET BANK AND TRUST COMPANY 505001	13,500	2.15
NORTHERN TRUST CO.(AVFC) SUB A/C AMERICAN CLIENTS	12,529	1.99

Note: Percentage of shareholding excludes treasury stock (1,343,900 shares).

■ Distribution of Shares by Number of Shares Held



■ Composition of Shareholders



Corporate Information (As of the End of Fiscal 2024)

Sysmex Corporation

Established	February 20, 1968
Head Office	1-5-1, Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan
Inquiries	IR Department: TEL: +81-78-265-0500
Website	https://www.sysmex.co.jp/en/
Number of Employees	11,457 (consolidated basis) (including part-time employees and others)
Fiscal Year	April 1–March 31
Shareholders' Meeting	June
Number of Shares Authorized	1,796,064,000 shares
Number of Shares Issued	629,473,176 shares
Paid-in Capital	¥14,887.8 million
Stock Listings	Tokyo Stock Exchange, Prime Market
Ticker Code	6869
Transfer Agent	Mitsubishi UFJ Trust and Banking Corporation
Independent Auditor	Deloitte Touche Tohmatsu LLC
Rating	AA- (Rating and Investment Information, Inc. (R&I))
Major Indexes	Dow Jones Best-in-Class World Index Dow Jones Best-in-Class Asia Pacific Index FTSE4Good Index Series FTSE Blossom Japan Index FTSE Blossom Japan Sector Relative Index Morningstar Japan ex-REIT Gender Diversity Tilt Index MSCI ESG Selection Indexes MSCI SRI Indexes MSCI Japan ESG Select Leaders Index MSCI Japan Empowering Women Index (WIN) S&P/JPX Carbon Efficient Index ISS ESG "Prime" Status Ethibel Excellence Ethibel Pioneer Ethibel Sustainability Index (ESI) Euronext Vigeo Eiris World 120 Index iSTOXX MUTB Japan Platinum Career 150 Index

FTSE4Good
FTSE Blossom Japan
FTSE Blossom Japan Sector Relative Index
MSCI Selection Indexes Constituents 2025
2025 CONSTITUENT MSCI NIHONKABU ESG SELECT LEADERS INDEX
2025 CONSTITUENT MSCI JAPAN EMPOWERING WOMEN INDEX (WIN)
S&P/JPX Carbon Efficient Index
STOXX INDICES
Member 2025/2026 Platinum Career Index

>>Website >Sustainability >External Evaluation